Biogen (LTS:0R1B) Cyclically Adjusted Book per Share: $94.48 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R1B Biogen Inc LTS:0R1B
77 GF Score
Price $196.20
GF Value $196.08
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Biogen Cyclically Adjusted Book per Share?

Biogen LTS:0R1B -6.25% 77 Cyclically Adjusted Book per Share is $94.48 as of Mar. 2026. GuruFocus rates LTS:0R1B with a GF Score™ of 77/100 and a GF Value™ of $196.08 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Biogen's adjusted book value per share for the three months ended in Mar. 2026 was $126.367. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $94.48 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Biogen's average Cyclically Adjusted Book Growth Rate was 10.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 10.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 12.00% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 12.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Biogen was 60.90% per year. The lowest was 8.90% per year. And the median was 13.60% per year.

As of today (2026-07-15), Biogen's current stock price is $196.20. Biogen's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $94.48. Biogen's Cyclically Adjusted PB Ratio of today is 2.08.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Biogen was 9.94. The lowest was 1.31. And the median was 4.81.


Biogen  (LTS:0R1B) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Biogen's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=196.20/94.48
=2.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Biogen was 9.94. The lowest was 1.31. And the median was 4.81.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Biogen Cyclically Adjusted Book per Share Related Terms


Biogen Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Biogen's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Cyclically Adjusted Book per Share Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.50 68.98 77.72 84.88 93.88

Biogen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 87.32 88.91 92.24 93.88 94.48

LTS:0R1B vs OGN, AMRN, SCLX: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted PB Ratio falls into.


LTS:0R1B
77GF Score
Biogen Inc LTS:0R1B
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biogen's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=126.367/330.2130*330.2130
=126.367

Current CPI (Mar. 2026) = 330.2130.

Biogen Quarterly Data

Book Value per Share CPI Adj_Book
201606 52.043 241.018 71.303
201609 55.694 241.428 76.175
201612 56.204 241.432 76.872
201703 53.640 243.801 72.652
201706 54.794 244.955 73.865
201709 60.813 246.819 81.360
201712 59.635 246.524 79.880
201803 66.603 249.554 88.130
201806 60.865 251.989 79.759
201809 68.326 252.439 89.377
201812 66.124 251.233 86.911
201903 70.850 254.202 92.035
201906 70.091 256.143 90.360
201909 76.943 256.759 98.955
201912 76.597 256.974 98.428
202003 74.996 258.115 95.944
202006 71.438 257.797 91.505
202009 69.906 260.280 88.689
202012 70.212 260.474 89.010
202103 70.931 264.877 88.427
202106 72.112 271.696 87.643
202109 71.000 274.310 85.469
202112 74.124 278.802 87.792
202203 76.219 287.504 87.541
202206 81.767 296.311 91.122
202209 88.719 296.808 98.704
202212 93.041 296.797 103.516
202303 95.280 301.836 104.238
202306 99.910 305.109 108.130
202309 99.957 307.789 107.239
202312 102.135 306.746 109.949
202403 105.062 312.332 111.077
202406 109.807 314.175 115.412
202409 112.278 315.301 117.588
202412 114.714 315.605 120.024
202503 115.896 319.799 119.670
202506 120.286 322.561 123.140
202509 124.114 324.800 126.182
202512 124.365 324.054 126.729
202603 126.367 330.213 126.367

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $94.48 mean?
Biogen (LTS:0R1B) has a Cyclically Adjusted Book per Share of $94.48 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Biogen and its competitors.
Is Biogen's Cyclically Adjusted Book per Share too high?
Biogen's current Cyclically Adjusted Book per Share is $94.48. Overall, Biogen has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biogen's Cyclically Adjusted Book per Share compare to OGN and AMRN?
Biogen's Cyclically Adjusted Book per Share of $94.48 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Biogen and its competitors. Biogen's current Cyclically Adjusted Book per Share is $94.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Based on GuruFocus' analysis, Biogen (LTS:0R1B) is currently considered Fairly Valued. The stock's GF Value™ is $196.08, compared to a current price of $196.20 — trading 0.1% above its estimated fair value. The current Cyclically Adjusted Book per Share is $94.48. Biogen's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Biogen (LTS:0R1B), the current Cyclically Adjusted Book per Share is $94.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogen (LTS:0R1B) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of $196.20 is trading 0.1% above its estimated GF Value™ of $196.08. GuruFocus considers Biogen to be Fairly Valued.

Key valuation signals for LTS:0R1B:

  • Cyclically Adjusted Book per Share: $94.48
  • GF Value™: $196.08 vs. price of $196.20 (0.1% above fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the LTS:0R1B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
77GF Score

Get the complete analysis for LTS:0R1B

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$196.20
Price
$196.08
GF Value